• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AC Immune SA (Amendment)

    2/9/24 4:30:11 PM ET
    $ACIU
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACIU alert in real time by email
    SC 13G/A 1 p129241sc13ga2.htm AMENDMENT NO. 2

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)

     

    AC IMMUNE SA

    (Name of Issuer)

     

    Common Shares

    (Title of Class of Securities)

     

    H00263105

    (CUSIP Number)

     

     

    December 15, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

     

    o Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     1 
     

     

    CUSIP No.  

    H00263105

                   

     

     

    1  

    NAMES OF REPORTING PERSONS

    Affiris AG in Liqu

         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
     
      (a)   o
      (b)   x
    3   SEC USE ONLY
       
       
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Austria
      5   SOLE VOTING POWER
         
    NUMBER OF   6,578,100
    SHARES 6   SHARED VOTING POWER
    BENEFICIALLY    
    OWNED BY   0
    EACH 7   SOLE DISPOSITIVE POWER
    REPORTING    
    PERSON   6,578,100
    WITH: 8   SHARED DISPOSITIVE POWER
         
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      6,578,100
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      6.66%
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

     

     2 
     

     

    Item 1.

     

    (a) Name of issuer:

     

    AC Immune SA

     

    (b) Address of issuer's principal executive offices:

     

    EPFL Innovation Park, bâtiment B, 1015 Lausanne, Switzerland

     

    Item 2.

     

    (a) Names of persons filing:

     

    Affiris AG in Liqu ("Affiris")

     

    (b) Addresses or principal business offices or, if none, residence:

     

    For Affiris, Karl-Farkas-Gasse 22, 1030 Vienna, Austria

     

    (c) Citizenship:

     

    For Affiris, Austria. 

     

    (d) Title of class of securities:

     

    Ordinary shares.

     

    (e) CUSIP No.: H00263105

     

    Item 3. If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:

     

    Not applicable. 

     

    Item 4. Ownership

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a) Amount beneficially owned:

     

    6,578,100 shares

     

    (b) Percent of class:

     

    See line 11 of the cover sheet. The percentage set forth is based on 98,749,352 shares of the issuer that were reported as outstanding as of December 19, 2023.

     

     3 
     

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

     

    See line 5 of the cover sheet.

     

    (ii) Shared power to vote or to direct the vote:

     

    See line 6 of the cover sheet.

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    See line 7 of the cover sheet.

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    See line 8 of the cover sheet.

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certifications

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     4 
     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    AFFIRIS AG in Liqu    
           
           
    By: /s/ Claus Schalper    
    Name: Claus Schalper    
    Title: Chief Executive Officer    

     

     

    5

     

     

    Get the next $ACIU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACIU

    DatePrice TargetRatingAnalyst
    5/31/2024$8.00Buy
    BTIG Research
    12/20/2021$17.00 → $15.00Outperform
    SVB Leerink
    More analyst ratings

    $ACIU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on AC Immune with a new price target

      BTIG Research initiated coverage of AC Immune with a rating of Buy and set a new price target of $8.00

      5/31/24 7:33:11 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on AC Immune with a new price target

      SVB Leerink reiterated coverage of AC Immune with a rating of Outperform and set a new price target of $15.00 from $17.00 previously

      12/20/21 4:45:45 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on AC Immune with a new price target

      HC Wainwright & Co. reiterated coverage of AC Immune with a rating of Buy and set a new price target of $16.00 from $11.00 previously

      3/24/21 6:35:50 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACIU
    SEC Filings

    See more
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      4/30/25 7:15:09 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AC Immune SA

      6-K - AC Immune SA (0001651625) (Filer)

      3/13/25 7:32:22 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by AC Immune SA

      20-F - AC Immune SA (0001651625) (Filer)

      3/13/25 7:30:34 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACIU
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ACIU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ACIU
    Leadership Updates

    Live Leadership Updates

    See more
    • AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

      AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizationsRepeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titersACI-7104.056 is well tolerated with no safety issues reported to date Lausanne, Switzerland, April 2, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced

      4/2/25 6:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

      AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company's industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseasesMultiple presentations at the International Conference on Alzheimer's and Parkinson's Disease (AD/PD™ 2025) showcasing the diversity of the company's precision medicine pipeline Lausanne, Switzerland, March 25, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine

      3/25/25 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune to Participate in Upcoming Investor Conferences

      AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in the following investor conferences in March: Leerink Partners 2025 Global Healthcare Conference,Management will participate in investor meetings on March 10, 2025Barclays 27th Annual Global Healthcare Conference,Management will participate in investor meetings on March 11, 2025 Please contact your Leerink or Barclays representative or AC Immune to request a one-on-one meeting with AC Immune's manag

      3/4/25 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AC Immune SA

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      12/13/24 5:15:16 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by AC Immune SA

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      11/14/24 4:36:20 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by AC Immune SA (Amendment)

      SC 13G/A - AC Immune SA (0001651625) (Subject)

      2/9/24 4:30:11 PM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

      AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO Outstanding scientist and entrepreneur Dr. Madiha Derouazi appointed as new CSORetiring CSO Dr. Marie Kosco-Vilbois will remain as consultant to ensure smooth handoverChristopher Roberts, Interim Chief Financial Officer, confirmed in role on a permanent basis Lausanne, Switzerland, December 1, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Off

      12/1/23 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune SA Appoints New Chief Medical Officer

      AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee member Lausanne, Switzerland, July 26, 2023 – AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the appointment of Nuno Mendonça, MD. He will join the Company on October 1st, as Chief Medical Officer and be appointed to the Executive Committee. Johannes Streffer, MD, currently Chief Medical Officer, will leave at the end of September to pursue a new role. Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: "It is with great pleasure that we welcome Dr Mendonça to our

      7/26/23 7:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors

      Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization Prof. Bütler is a leading Swiss economist and former Vice President of the independent Swiss COVID-19 Science Taskforce LAUSANNE, Switzerland, Oct. 29, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held an extraordinary general meeting (EGM) and elected Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors. Dr. Shaw and Prof. Bütler replace Mr. M

      10/29/21 6:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ACIU
    Financials

    Live finance-specific insights

    See more
    • AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

      AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer's disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC Immune to host conference call and webcast today at 8:30 a.m. ET OSAKA, Japan, CAMBRIDGE, Massachusetts, and LAUSANNE, Switzerland, May 13, 2024 – Takeda (NYSE:TAK) and AC Immune SA (NASDAQ:ACIU)

      5/13/24 6:00:00 AM ET
      $ACIU
      $TAK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune acquires AFFiRiS' Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

      AFFiRiS to receive AC Immune stock valued at USD 58.7 million in exchange for its portfolio of therapeutics targeting alpha-synuclein and USD 5 million in cashAFFiRiS to focus on partnering to further develop its SAIT and monoclonal antibody for cardiovascular disease and for Huntington's disease, respectively VIENNA, Austria, July 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company that has been engaged in the development of novel disease-modifying Specific Active Immunotherapies (SAITs), today announced that AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, is acquiring AFFiRiS

      7/27/21 8:00:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AC Immune Announces Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

      All-stock transaction maintains AC Immune's strong cash position USD 25 million private placement led by premier investor Athos Service GmbH Transactions expand and accelerate AC Immune's therapeutic development in Parkinson's disease AC Immune to immediately launch clinical development of acquired vaccine into an adaptive, biomarker-based Phase 2 study in Parkinson's disease Conference call scheduled today at 8:30 am ET / 2:30 pm CET LAUSANNE, Switzerland, July 27, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that it is acquiring Affiris' portfoli

      7/27/21 7:30:00 AM ET
      $ACIU
      Biotechnology: Pharmaceutical Preparations
      Health Care